A Director at Adamas Pharmaceuticals is Exercising Options


Yesterday it was reported that a Director at Adamas Pharmaceuticals (ADMS), David L. Mahoney, exercised options to buy 33,332 ADMS shares at $1.75 a share, for a total transaction value of $58.33K. The options were close to expired and David L. Mahoney retained stocks.

Following this transaction David L. Mahoney’s holding in the company was increased by 126.02% to a total of $396.9K.

See today’s analyst top recommended stocks >>

Based on Adamas Pharmaceuticals’ latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $12.69 million and GAAP net loss of $24.87 million. In comparison, last year the company earned revenue of $7.57 million and had a GAAP net loss of $33.99 million. The company has a one-year high of $20.63 and a one-year low of $4.20. Currently, Adamas Pharmaceuticals has an average volume of 457.87K.

Four different firms, including Evercore ISI and Northland Securities, currently also have a Buy rating on the stock.

Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts